A Phase 3 interventional study of Adalimumab and Placebo in Crohn's Disease, sponsored by AbbVie. Completed at 143 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 22 in phase 3, and was the 26th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 514 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2014, is one of 16 in phase 3, and was the 15th registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
Drug: Adalimumab · Drug: Placebo
Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
Drug: Adalimumab
Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
Drug: Adalimumab
At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
Drug: Adalimumab
Also known as: Humira
Percentage of Participants Who Achieved Clinical Remission at Week 4
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
Time frame: Week 4
Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response was scored using the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \> 50% from Baseline (or for a Baseline SES-CD of 4, at least a 2 point reduction from Baseline) at Week 12.
Time frame: Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. Serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. TEAEs: any event that began or worsened in severity after the first dose of study drug in the induction or maintenance study. Events with unknown severity were counted as severe. Events with unknown relationship to study drug were counted as drug-related.
Time frame: From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).
Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12
CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
Time frame: Week 4 and Week 12
Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12
Clinical response was scored using CDAI, which assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline. Endoscopic response was scored using the SES-CD, which evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \>50% from Baseline (or for Baseline SES-CD of 4, at least a 2-point reduction from Baseline) at Week 12.
Time frame: Week 12
Percentage of Participants With Clinical Remission at Week 12
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
Time frame: Week 12
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
Time frame: Week 12
Percentage of Participants With Endoscopic Remission at Week 12
Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.
Time frame: Week 12
Change From Baseline in Fecal Calprotectin Level at Week 4
Time frame: Baseline, Week 4
Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4
Time frame: Week 4
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
Time frame: Week 4
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 12
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.
Time frame: Week 12
Percentage of Participants Who Achieved an SES-CD ≤ 2 at Week 12
The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease.
Time frame: Week 12
Percentage of Participants With Clinical Response at Week 4
Clinical response was scored using CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from baseline.
Time frame: Week 4
Percentage of Participants With Clinical Response at Week 12
Clinical response was scored using CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline.
Time frame: Week 12
Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.
Time frame: Week 4
Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.
Time frame: Week 12
Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.
Time frame: Week 12
| Milestone | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Maintenance: Clinically Adjusted (CA) Regimen | Maintenance: Therapeutic Drug Monitoring (TDM) Regimen |
|---|---|---|---|---|
| Started | 206 | 308 | 0 | 0 |
| Completed | 192 | 287 | 0 | 0 |
| Not completed | 14 | 21 | 0 | 0 |
| Withdrew: Adverse event | 5 | 12 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Other, not specified | 6 | 5 | 0 | 0 |
| Milestone | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Maintenance: Clinically Adjusted (CA) Regimen | Maintenance: Therapeutic Drug Monitoring (TDM) Regimen |
|---|---|---|---|---|
| Started | 0 | 0 | 109 | 109 |
| Completed | 0 | 0 | 87 | 90 |
| Not completed | 0 | 0 | 22 | 19 |
| Withdrew: Adverse event | 0 | 0 | 8 | 8 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 |
| Withdrew: Other, not specified | 0 | 0 | 11 | 5 |
Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 4 | 43.7 | 43.5 |
Endoscopic response was scored using the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \> 50% from Baseline (or for a Baseline SES-CD of 4, at least a 2 point reduction from Baseline) at Week 12.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 12 | 39.3 | 42.9 |
Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. Serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. TEAEs: any event that began or worsened in severity after the first dose of study drug in the induction or maintenance study. Events with unknown severity were counted as severe. Events with unknown relationship to study drug were counted as drug-related.
| Participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Maintenance: Clinically Adjusted (CA) Regimen | Maintenance: Therapeutic Drug Monitoring (TDM) Regimen |
|---|---|---|---|---|
| Any TEAE | 133 | 185 | 77 | 76 |
| TEAE w/reasonable possibility of being related to study drug | 54 | 75 | 29 | 33 |
| Any severe TEAE | 13 | 17 | 7 | 6 |
| Any SAE | 10 | 14 | 5 | 7 |
| Any TEAE leading to discontinuation of study drug | 8 | 13 | 8 | 9 |
| Any TEAE leading to death | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12 | 35.0 | 39.0 |
Clinical response was scored using CDAI, which assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline. Endoscopic response was scored using the SES-CD, which evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \>50% from Baseline (or for Baseline SES-CD of 4, at least a 2-point reduction from Baseline) at Week 12.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12 | 20.4 | 22.1 |
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Clinical Remission at Week 12 | 51.5 | 62.3 |
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline | 48.0 | 52.9 |
Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 12 | 26.2 | 28.6 |
| µg/g | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Change From Baseline in Fecal Calprotectin Level at Week 4 | -1045.7 ± 1648.51 | -1157.0 ± 2000.69 |
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4 | 27.7 | 32.5 |
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4 | 11.2 | 14.3 |
Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 12 | 7.3 | 11.7 |
The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Who Achieved an SES-CD ≤ 2 at Week 12 | 16.0 | 20.1 |
Clinical response was scored using CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from baseline.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Clinical Response at Week 4 | 70.9 | 74.4 |
Clinical response was scored using CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants With Clinical Response at Week 12 | 74.8 | 83.4 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4 | 71.4 | 74.7 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12 | 73.3 | 76.9 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.
| percentage of participants | Induction: Standard Induction Dose | Induction: Higher Induction Dose |
|---|---|---|
| Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12 | 68.4 | 76.0 |
Collected over From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction: Standard Induction Dose | 0/206 (0%) | 10/206 (4.9%) | 54/206 (26.2%) |
| Induction: Higher Induction Dose | 0/308 (0%) | 14/308 (4.5%) | 58/308 (18.8%) |
| Maintenance: Clinically Adjusted (CA) Regimen | 0/109 (0%) | 5/109 (4.6%) | 41/109 (37.6%) |
| Maintenance: Therapeutic Drug Management (TDM) Regimen | 0/109 (0%) | 7/109 (6.4%) | 33/109 (30.3%) |
| Event | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Maintenance: Clinically Adjusted (CA) Regimen | Maintenance: Therapeutic Drug Management (TDM) Regimen |
|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 3/206 | 3/308 | 2/109 | 1/109 |
| SCLERITISEye disorders | 0/206 | 0/308 | 0/109 | 1/109 |
| UVEITISEye disorders | 0/206 | 0/308 | 0/109 | 1/109 |
| INTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/206 | 0/308 | 0/109 | 1/109 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/206 | 2/308 | 1/109 | 0/109 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/206 | 0/308 | 1/109 | 0/109 |
| INFECTIOUS MONONUCLEOSISInfections and infestations | 0/206 | 0/308 | 0/109 | 1/109 |
| SEPSISInfections and infestations | 0/206 | 0/308 | 0/109 | 1/109 |
| URINARY TRACT INFECTIONInfections and infestations | 0/206 | 1/308 | 0/109 | 1/109 |
| VARICELLAInfections and infestations | 0/206 | 0/308 | 0/109 | 1/109 |
| Event | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Maintenance: Clinically Adjusted (CA) Regimen | Maintenance: Therapeutic Drug Management (TDM) Regimen |
|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 12/206 | 14/308 | 16/109 | 15/109 |
| NASOPHARYNGITISInfections and infestations | 9/206 | 19/308 | 15/109 | 10/109 |
| HEADACHENervous system disorders | 18/206 | 17/308 | 9/109 | 8/109 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 16/206 | 10/308 | 8/109 | 4/109 |
| NAUSEAGastrointestinal disorders | 15/206 | 9/308 | 5/109 | 3/109 |
| DIARRHOEAGastrointestinal disorders | 3/206 | 2/308 | 6/109 | 4/109 |
| DIZZINESSNervous system disorders | 11/206 | 2/308 | 0/109 | 0/109 |
| Age, Continuous(years) | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Total |
|---|---|---|---|
| Mean | 36.4 ± 12.79 | 36.4 ± 13.02 | 36.4 ± 12.92 |
| Sex: Female, Male(Participants) | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Total |
|---|---|---|---|
| Female | 109 | 158 | 267 |
| Male | 97 | 150 | 247 |
| Ethnicity (NIH/OMB)(Participants) | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 10 | 15 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 201 | 298 | 499 |
| Race (NIH/OMB)(Participants) | Induction: Standard Induction Dose | Induction: Higher Induction Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 5 | 6 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 18 | 11 | 29 |
| White | 182 | 288 | 470 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
Showing the first 100 of 143 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from May 2014 to primary completion in Jan 2020, 68 months.
Results were first posted in Feb 2021, 1 year after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 68 months is above that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab